Clinical Trials Browser

Has results × Leukemia, Lymphocytic, Chronic, B-Cell × ibrutinib × Clear all

NCT01886872 2026-03-19

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 3 Active not recruiting

547 enrolled 19 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03462719 2026-03-12

GLOW

Phase 3 Active not recruiting

211 enrolled 23 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03514017 2026-03-02

Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

Phase 2 Terminated

5 enrolled 11 charts

LymphoidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02649387 2026-02-10

MERIT

Phase 2 Completed

35 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03204188 2026-01-30

Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Completed

15 enrolled 9 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02427451 2026-01-27

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

Phase 1/2 Active not recruiting

87 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04230304 2025-12-30

Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study

Phase 2 Terminated

8 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02048813 2025-11-28

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Active not recruiting

529 enrolled 12 charts 2 FDA

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02477696 2025-11-20

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Phase 3 Active not recruiting

533 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02251548 2025-10-24

iFCR

Phase 2 Active not recruiting

85 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02315768 2025-09-15

Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.

Phase 1/2 Completed

32 enrolled 9 charts

LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03207555 2025-09-02

Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed

23 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01589302 2025-07-25

PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Phase 2 Active not recruiting

154 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02303392 2025-06-10

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Phase 1 Completed

34 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT03190330 2025-05-25

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Phase 4 Completed

75 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03400176 2025-05-16

VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Phase 1 Terminated

39 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734016 2025-03-30

ALPINE

Phase 3 Completed

652 enrolled 27 charts 1 FDA

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02910583 2024-12-20

Captivate

Phase 2 Completed

323 enrolled 33 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02268851 2024-11-15

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

Phase 1 Completed

45 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01500733 2024-09-19

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2 Active not recruiting

86 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01724346 2024-09-19

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Completed

269 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02514083 2024-09-19

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Phase 2 Active not recruiting

29 enrolled 11 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02420912 2024-03-20

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Phase 2 Completed

37 enrolled 12 charts

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02332980 2024-01-03

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Phase 2 Completed

65 enrolled 21 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02869633 2023-10-23

Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Phase 2 Completed

23 enrolled 10 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04016805 2023-07-24

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Phase 2 Terminated

41 enrolled 4 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02301156 2022-05-20

GENUINE

Phase 3 Completed

126 enrolled 18 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04209621 2022-03-09

Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Phase 2 Terminated

3 enrolled 12 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03045328 2021-09-29

Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Phase 2 Completed

22 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02406742 2021-09-20

ENHANCE

Phase 1/2 Completed

47 enrolled 15 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02759016 2020-09-29

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

Phase 1 Completed

7 enrolled 8 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01109069 2020-05-27

Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Phase 2 Completed

199 enrolled 14 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT01611090 2020-03-03

A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 3 Completed

578 enrolled 21 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02801578 2020-02-27

A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)

Phase 2/3 Completed

11 enrolled 7 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01752426 2020-02-24

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

Phase 1/2 Completed

30 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01578707 2019-12-18

RESONATE™

Phase 3 Completed

391 enrolled 14 charts

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01520519 2019-09-18

Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Phase 2 Completed

40 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01973387 2018-07-24

A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma

Phase 3 Completed

160 enrolled 12 charts

LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01722487 2017-11-30

Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL

Phase 3 Completed

269 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01217749 2015-06-25

PCYC-1109-CA

Phase 1/2 Completed

71 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01292135 2014-07-24

Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)

Phase 1 Completed

33 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01105247 2014-03-31

Safety of PCI-32765 in Chronic Lymphocytic Leukemia

Phase 1/2 Completed

133 enrolled 10 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell